Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison.

Keeping, Sam

Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison. [electronic resource] - Expert review of hematology 06 2018 - 503-511 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Systematic Review

1747-4094

10.1080/17474086.2018.1475226 doi


Antibodies, Monoclonal, Humanized--adverse effects
Brentuximab Vedotin
Female
Hodgkin Disease--drug therapy
Humans
Immunoconjugates--adverse effects
Male